What AI says about GRAIL
Data as of Oct 20, 2026Based on 1,923 AI responses
Reviewed by Dimitry Apollonsky
AI summary
GRAIL is a healthcare company that provides the Galleri test, a blood-based multi-cancer early detection test that screens for more than 50 cancer types.
1%
across GRAIL’s markets · since Jul 5
GRAIL in AI’s own words
Question: As a 45-year-old with a family history of cancer, which early-detection blood test should I consider?
Google AI ModeSep 20, 2026
Multi-Cancer Early Detection (MCED) tests (such as the GRAIL Galleri Test Go to product viewer dialog for this item. ) are emerging liquid biopsies
Question: Which diagnostic AI tools are strongest for early detection using imaging, blood tests, or wearable signals?
ChatGPT SearchSep 3, 2026
GRAIL's Galleri analyzes DNA methylation patterns in cell-free DNA and uses machine learning to identify a cancer signal and predict its likely tissue of origin.
Question: As a 45-year-old with a family history of cancer, which early-detection blood test should I consider?
Google AI ModeJul 10, 2026
These tests, such as GRAIL's Galleri , can detect signals from many types of cancer
Where AI mentions GRAIL
Each engine’s share of its own answers across GRAIL’s markets · since Jul 5
- ChatGPT Search1%
- Google AI Mode1%
A cited page to review
This page is cited in 12% of the answers that name GRAIL.
Review this page on your site for accurate product details and clear explanations of who it helps.
All-time evidence through 2026-09-20.
Review the page on grail.com (opens in a new tab)
Questions and answers
- Mentioned in
- What's the best multi-cancer early-detection blood test available now?on this question21%
Excerpts where GRAIL appeared in the AI's answer
Google AI ModeSep 17, 2026, Google AI Mode The most widely known and clinically studied MCED test is the Galleri test developed by GRAIL.
Google AI ModeSep 5, 2026, Google AI Mode GRAIL’s Galleri Test: This is currently one of the most widely known and commercially available MCED tests
- As a 45-year-old with a family history of cancer, which early-detection blood test should I consider?on this question7%
Excerpts where GRAIL appeared in the AI's answer
Google AI ModeSep 20, 2026, Google AI Mode Multi-Cancer Early Detection (MCED) tests (such as the GRAIL Galleri Test Go to product viewer dialog for this item. ) are emerging liquid biopsies
Google AI ModeJul 10, 2026, Google AI Mode These tests, such as GRAIL's Galleri , can detect signals from many types of cancer
- As someone optimizing my healthspan, which full-body diagnostic is actually worth the money?on this question2%
Excerpts where GRAIL appeared in the AI's answer
Google AI ModeJul 17, 2026, Google AI Mode Grail Galleri Test: An emerging (not yet FDA-approved) blood test that can detect signals from 50+ cancers.
- Which diagnostic AI tools are strongest for early detection using imaging, blood tests, or wearable signals?on this question4%
Excerpts where GRAIL appeared in the AI's answer
Google AI ModeSep 3, 2026, Google AI Mode GRAIL (Galleri Test - Galleri/Multi-Cancer Early Detection): While not an isolated software tool, it uses sophisticated machine-learning classifiers
ChatGPT SearchSep 3, 2026, ChatGPT Search GRAIL's Galleri analyzes DNA methylation patterns in cell-free DNA and uses machine learning to identify a cancer signal and predict its likely tissue of origin.
Sources AI cites
grail.com 20%Other sites 80%
- Owned20%
- Multi-Cancer Early Detection - GRAIL · 7% (opens in a new tab)
- GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting - GRAIL · 4% (opens in a new tab)
- GRAIL: Home · 2% (opens in a new tab)
- GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri<sup>®</sup> Multi-Cancer Early Detection Test - GRAIL · 2% (opens in a new tab)
- GRAIL PATHFINDER 2 Results Show Galleri® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings - GRAIL · 2% (opens in a new tab)
- GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri<sup>®</sup> Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting - GRAIL · 2% (opens in a new tab)
- GRAIL Submits FDA Premarket Approval Application for the Galleri<sup>®</sup> Multi-Cancer Early Detection Test - GRAIL · 2% (opens in a new tab)
